Catalyst Dossier · compiled by CeliA 🧫

EyePoint Pharmaceuticals, Inc. (EYPT)

Laboratory Analytical Instruments · market cap $1.1B

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-05Earningsimp 5/10
2026-10-15 (est.)Phase 3 · Aflibercept (2.0 mg)imp 9/10
2026-10-15 (est.)Phase 3 · EYP-1901imp 9/10

Pipeline

Asset	Phase	Indication
Latanoprost ophthalmic solution	Phase 2	Ocular Hypertension
FAI insert	Phase 3	Non-Infectious Uveitis
Aflibercept 2mg/0.05mL Inj,Oph	Phase 2	Wet Age-related Macular Degeneration
Aflibercept (2.0 mg)	Phase 3	Wet Age Related Macular Degeneration
FAI Insert administered using the Mk II inserter	Phase 3	Non-Infectious Uveitis
EYP-1901	Phase 3	Diabetic Macular Edema
AKB-9778	Phase 2	Nonproliferative Diabetic Retinopathy

Price & technical context

3-month

+2.4%

6-month

-27.5%

12-month

+40.2%

52-wk range

$9.49–$18.85

vs 50-day MA

+0.2%

vs 200-day MA

-6.6%

Realized vol

64.5%

Max drawdown

-65.9%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for EYPT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.